Thyrotoxicosis after Denileukin Diftitox Therapy in Patients with Mycosis Fungoides

Ghori, Farah; Polder, Kristel D.; Pinter‐Brown, Lauren; Hoff, Ana O.; Gagel, Robert F.; Sherman, Steven I.; Duvic, Madeleine

doi:10.1210/jc.2005-2839

Cited by 29 publications

(14 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is approved for use in cutaneous T-cell lymphoma and graft-versus-host disease after allogenic stem cell transplant (86,87). In a retrospective study, eight patients showed TPO-Ab and thyrotoxicosis within 1-35 days of treatment; five of them eventually developed permanent hypothyroidism (88). Autoimmunity could not be the mechanism of DD-induced thyroid toxicity, because the IL2-component of the drug does not activate the IL2-lymphocyte receptor.…”

Section: Denileukin Diftitoxmentioning

confidence: 99%

“…Autoimmunity could not be the mechanism of DD-induced thyroid toxicity, because the IL2-component of the drug does not activate the IL2-lymphocyte receptor. The absence of IL2-receptors on thyrocytes excludes direct thyroid toxicity (88). However, DD might target and lyse intrathyroidal lymphocytes with local release of cytokines leading to thyroiditis/ thyrotoxicosis (88).…”

Section: Denileukin Diftitoxmentioning

confidence: 99%

See 1 more Smart Citation

Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs

Torino

Barnabei²,

Paragliola

et al. 2013

Thyroid

104

View full text Add to dashboard Cite

Section: Denileukin Diftitoxmentioning

confidence: 99%

Section: Denileukin Diftitoxmentioning

confidence: 99%

Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs

Torino

Barnabei²,

Paragliola

et al. 2013

Thyroid

104

View full text Add to dashboard Cite

“…Of note, Dd should not be administered in a facility ill equipped to provide cardiopulmonary resuscitation. Severe and persistent transaminitis, thyrotoxicosis, loss of visual acuity or color vision, and rhabdomyolysis have been reported but are uncommon [240,[246][247][248]. Investigations combining Dd with conventional chemotherapeutic agents are ongoing.…”

Section: Denileukin Diftitoxmentioning

confidence: 99%

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Wilcox

2011

American J Hematol

View full text Add to dashboard Cite

Disease overview: Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell lymphoproliferative disorders involving the skin, the majority of which may be classified as Mycosis fungoides (MF) or Sézary syndrome (SS).Diagnosis: The diagnosis of MF or SS requires the integration of clinical and histopathologic data.Risk‐adapted therapy: Tumor, node, metastasis, and blood (TNMB) staging remains the most important prognostic factor in MF/SS and forms the basis for a “risk‐adapted,” multidisciplinary approach to treatment. For patients with disease limited to the skin, expectant management or skin‐directed therapies is preferred, as both disease‐specific and overall survival for these patients is favorable. In contrast, patients with advanced‐stage disease with significant nodal, visceral, or blood involvement are generally approached with biologic‐response modifiers, denileukin diftitox, and histone deacetylase inhibitors before escalating therapy to include systemic, single‐agent chemotherapy. Multiagent chemotherapy may be used for those patients with extensive visceral involvement requiring rapid disease control. In highly‐selected patients with disease refractory to standard treatments, allogeneic stem‐cell transplantation may be considered. Am. J. Hematol., 2011. © 2011 Wiley‐Liss, Inc.

show abstract

“…Thyrotoxicosis has been identified in patients treated with interferon-a interleukin, lithium, denileukin diftitox, and leuprolide acetate (108,109,(165)(166)(167)(168)(169). Usually these medications cannot be stopped; therefore, the key is to determine whether the thyroid has high or low uptake of 123 I.…”

Section: Thyrotoxicosis Attributable To Nonthyroid Medicationsmentioning

confidence: 99%

“…The key is to obtain an uptake measurement, and when the value is low the course is similar to that of silent thyroiditis (165,176). Eight patients with mycosis fungoides became thyrotoxic during treatment with denileukin diftitox (167). Denileukin diftitox is a recombinant fusion protein consisting of the ligand binding region of interleukin 2 and diphtheria toxin.…”

Section: Thyrotoxicosis Attributable To Nonthyroid Medicationsmentioning

confidence: 99%

Uncommon Causes of Thyrotoxicosis

Mittra¹,

Niederkohr²,

Rodríguez³

et al. 2008

J Nucl Med

View full text Add to dashboard Cite

Apart from the common causes of thyrotoxicosis, such as Graves' disease and functioning nodular goiters, there are more than 20 less common causes of elevated free thyroid hormones that produce the symptoms and signs of thyrotoxicosis. This review describes these rarer conditions and includes 14 illustrative patients. Thyrotropin and free thyroxine should be measured and, when the latter is normal, the free triiodothyronine level should be obtained. Measurement of the uptake of 123 I is recommended for most patients.

show abstract

Thyrotoxicosis after Denileukin Diftitox Therapy in Patients with Mycosis Fungoides

Abstract: Monitoring thyroid function before and during treatment with denileukin diftitox is recommended. Symptomatic thyrotoxicosis may be missed due to other acute reactions to the drug, and subsequent hypothyroidism may develop.

Cited by 29 publications

References 22 publications

Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs

Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Uncommon Causes of Thyrotoxicosis

Contact Info

Product

Resources

About